Beta-NAD+ Encyclopedia — Scientific Background

What Is Beta-NAD+?

β-Nicotinamide adenine dinucleotide (β-NAD⁺, CAS 53-84-9), also known as nicotinamide adenine dinucleotide, coenzyme I, or β-NAD, is a pyridine nucleotide with the molecular formula C₂₁H₂₇N₇O₁₄P₂ and a molecular weight of 663.43 g/mol. The compound consists of two nucleotides joined through their phosphate groups, with one nucleotide containing an adenine nucleobase and the other containing nicotinamide. It occurs as a white to off-white crystalline powder that is freely soluble in water.

Physiological Functions of NAD⁺

NAD⁺ is critical for numerous physiological functions:

• Cellular Energy Metabolism — NAD⁺ is an essential electron carrier in the mitochondrial electron transport chain, required for ATP synthesis through oxidative phosphorylation. It is indispensable for glycolysis, the TCA cycle, and fatty acid β-oxidation.

• DNA Repair — NAD⁺ is the substrate for poly(ADP-ribose) polymerases (PARPs), enzymes that catalyze the transfer of ADP-ribose units to acceptor proteins at sites of DNA damage. This PARP-mediated DNA repair mechanism is essential for genomic stability.

• Sirtuin Activation — NAD⁺ is a required cofactor for sirtuin enzymes (SIRT1–SIRT7), which regulate gene expression, DNA repair, and cellular stress responses. Sirtuin activation is associated with improved metabolic function and longevity-related pathways.

• Circadian Rhythm Regulation — NAD⁺ levels oscillate with the circadian clock and influence metabolic rhythms.

• Epigenetic Regulation — NAD⁺ serves as a cofactor for enzymes involved in epigenetic modifications, including histone deacetylation and DNA methylation.

Mechanisms of Action

Redox Cofactor Function

NAD⁺ functions as a crucial redox cofactor and signaling molecule that regulates cellular metabolism, genome stability, and stress responses.NAD⁺ controls energy homeostasis, DNA repair, epigenetic conditions, and circadian rhythms by dynamically regulating NAD⁺-dependent enzyme systems, the most notable of which are sirtuins and poly(ADP-ribose) polymerases, making NAD⁺ the hub of health, ageing, and disease.

Mitochondrial Function and Energy Production

NAD⁺ is required for fatty acid metabolism during β-oxidation, glutaminolysis generating α-ketoglutarate, mitochondrial shuttling of metabolites, and lactic acid fermentation.Declining levels of NAD⁺ are associated with general aging and chronic disorders, including cognitive decline and sarcopenia, highlighting the role of NAD⁺ in mitochondrial homeostasis in aging and disease conditions.

liposomal Encapsulation and Enhanced Bioavailability

A liposomal formulation of NAD⁺ (LF-NAD⁺) was tested in primary human aortic endothelial cells (HAECs) and primary human epidermal keratinocytes (HEKas). Compared to control NAD⁺ alone, the LF-NAD⁺ formulation increased the intracellular NAD⁺ content and cell survival in HAECs. A significant reduction in the number of senescent cells was observed in both HAECs and HEKas. LF-NAD⁺ treatment was associated with a reduced expression of p16 in both cell types and a significant reduction in p21 in HEKas alone. Finally, LF-NAD⁺ increased the skin penetration of the active substance NAD⁺ by 30% compared to the application of NAD⁺ alone.

Clinical data demonstrates that Liposomal NAD⁺ achieves 1.52-fold higher bioavailability compared to conventional forms, with 9 times higher NAD⁺ concentration in the liver.

The Bioavailability Challenge

Despite its essential physiological functions, native NAD⁺ presents significant bioavailability challenges. The large molecular weight and complex structure of NAD⁺ make it difficult to penetrate cell membranes, resulting in challenging effective absorption and utilization by the human body.NAD⁺ has poor physicochemical stability and is easily broken down under room temperature and high-temperature conditions, which also limits its application as tablets and capsules.Low bioavailability and stability of NAD⁺ formulations are the main factors limiting its effectiveness as an anti-aging treatment.

These limitations have driven the development of advanced delivery systems, including liposomal encapsulation. A clinical study is evaluating whether liposomal encapsulation significantly enhances oral bioavailability of NAD⁺ compared to native NAD⁺ in healthy adults using a randomized, double-blind, crossover design.

Liposomal Beta-NAD+

Liposomal encapsulation of β-NAD⁺ provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the NAD⁺ molecule, forming a protective shell that enhances stability, bioavailability, and cellular uptake. This delivery system:

• Achieves 1.52-fold higher bioavailability compared to conventional forms

• Achieves 9 times higher NAD⁺ concentration in the liver

• Significantly reduces the number of senescent cells in endothelial cells and keratinocytes

• Increases skin penetration of NAD⁺ by 30% compared to free NAD⁺

• Provides an average particle size of 29 nm for efficient cellular uptake

Clinical Evidence

Friedreich‘s Ataxia — Randomized Controlled Trial

A 12-week, outpatient, phase 2, single-site, randomized, 2 × 2 factorial clinical trial evaluated the effect of exercise and NAD⁺ precursor supplementation with nicotinamide riboside in individuals aged 10–40 years with Friedreich’s ataxia. Weight-based dosing of nicotinamide riboside was 300 mg for weights of 24–48 kg, 600 mg for weights of 48–72 kg, and 900 mg for weights over 72 kg. The study demonstrated safety and tolerability of NAD⁺ precursor supplementation in this population.

Mild Cognitive Impairment — Randomized Controlled Trial

A 12-week double-blind, placebo-controlled pilot study evaluated the safety, tolerability, and preliminary efficacy of nicotinamide riboside (500 mg twice daily) for enhancing cognitive function and cerebral perfusion in older adults with mild cognitive impairment.

Long COVID Fatigue and Brain Fog — Clinical Trial

A clinical trial safely demonstrated that high-dose nicotinamide riboside (2,000 mg daily) can boost NAD⁺ levels in long COVID patients, with 37 people taking 2,000 mg of NR daily for 20 weeks.

Safety and Regulatory

Liposomal NAD⁺ is generally well tolerated, with reported responses typically mild, temporary, and individual-dependent.Research and user observations suggest that liposomal NAD⁺ is generally well tolerated, though mild and temporary responses may occur in some individuals, particularly during initial use. Most reported effects are mild, temporary, and linked to dose or individual sensitivity. Common side effects include mild nausea, headaches, or fatigue, especially when starting or using higher doses. These usually ease as the body adjusts or when the dose is lowered.

Regulatory Status:

• United States — NAD⁺ is regulated as a dietary supplement ingredient. It is commercialized in various dosage forms including capsules, liquid packets, and powders.

• Global Standards — NAD⁺ is available with GMP certification, third-party testing, and is generally gluten-free and sugar-free. Commercial products are available as vegan, non-GMO formulations.

Precautions: Individuals with known hypersensitivity to NAD⁺ or related compounds should avoid supplementation. Pregnant or lactating women and children should consult a healthcare professional before use. NAD⁺ may interact with certain medications; consult a healthcare professional if taking prescription drugs.

Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

199$/KG

159$/KG